Cancer development is driven by the accumulation of alterations affecting the structure and
function of the genome. Whereas genetic changes disrupt the DNA sequence, epigenetic …

Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …

The genetic information of human cells is stored in the context of chromatin, which is
subjected to DNA methylation and various histone modifications. Such a 'language'of …

The transcriptional upregulation of oncogenes is a driving force behind the progression of
many tumours. However, until a decade ago, the concept of 'switching off'these oncogenic …

ADP-ribosylation (ADPRylation) is a post-translational modification of proteins catalyzed by
ADP-ribosyl transferase (ART) enzymes, including nuclear PARPs (eg, PARP1 and PARP2) …

Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …

Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …

Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA
damage response (DDR) and/or increased replication stress. These alterations promote the …

Pharmacologic inhibition of PARP is the primary therapeutic strategy for BRCA mutant
ovarian cancer. However, most of patients carry wild-type BRCA1/2 with no significant …

Epigenetic dysregulation has long been recognized as a key factor contributing to
tumorigenesis and tumour maintenance that can influence all of the recognized hallmarks of …